AR056254A1 - SISTEMAS DE ADMINISTRACION INTRAOCULAR DE UNA DROGA DE LIBERACION SOSTENIDA QUE CONTIENE RETINOIDES, UN POLíMERO BIODEGRADABLE Y LOS METODOS RELACIONADOS - Google Patents
SISTEMAS DE ADMINISTRACION INTRAOCULAR DE UNA DROGA DE LIBERACION SOSTENIDA QUE CONTIENE RETINOIDES, UN POLíMERO BIODEGRADABLE Y LOS METODOS RELACIONADOSInfo
- Publication number
- AR056254A1 AR056254A1 ARP050101751A ARP050101751A AR056254A1 AR 056254 A1 AR056254 A1 AR 056254A1 AR P050101751 A ARP050101751 A AR P050101751A AR P050101751 A ARP050101751 A AR P050101751A AR 056254 A1 AR056254 A1 AR 056254A1
- Authority
- AR
- Argentina
- Prior art keywords
- biodegradable polymer
- sustained release
- related methods
- drug containing
- release drug
- Prior art date
Links
- 239000004621 biodegradable polymer Substances 0.000 title abstract 3
- 229920002988 biodegradable polymer Polymers 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000013268 sustained release Methods 0.000 title 1
- 239000012730 sustained-release form Substances 0.000 title 1
- 239000007943 implant Substances 0.000 abstract 3
- 239000011159 matrix material Substances 0.000 abstract 2
- 150000004492 retinoid derivatives Chemical class 0.000 abstract 2
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- 239000004372 Polyvinyl alcohol Substances 0.000 abstract 1
- 208000002158 Proliferative Vitreoretinopathy Diseases 0.000 abstract 1
- 206010057430 Retinal injury Diseases 0.000 abstract 1
- 206010038934 Retinopathy proliferative Diseases 0.000 abstract 1
- 208000021971 neovascular inflammatory vitreoretinopathy Diseases 0.000 abstract 1
- 229920002451 polyvinyl alcohol Polymers 0.000 abstract 1
- 230000006785 proliferative vitreoretinopathy Effects 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56733904P | 2004-04-30 | 2004-04-30 | |
US62992804P | 2004-11-22 | 2004-11-22 | |
US11/119,024 US20050271705A1 (en) | 2004-04-30 | 2005-04-29 | Retinoid-containing sustained release intraocular drug delivery system and related methods |
Publications (1)
Publication Number | Publication Date |
---|---|
AR056254A1 true AR056254A1 (es) | 2007-10-03 |
Family
ID=34972221
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050101751A AR056254A1 (es) | 2004-04-30 | 2005-05-02 | SISTEMAS DE ADMINISTRACION INTRAOCULAR DE UNA DROGA DE LIBERACION SOSTENIDA QUE CONTIENE RETINOIDES, UN POLíMERO BIODEGRADABLE Y LOS METODOS RELACIONADOS |
Country Status (9)
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
JP2007529434A (ja) | 2004-03-17 | 2007-10-25 | ラース マイケル ラーセン, | 視覚サイクルの阻害による網膜症の予防 |
US20070212395A1 (en) * | 2006-03-08 | 2007-09-13 | Allergan, Inc. | Ocular therapy using sirtuin-activating agents |
US9498457B2 (en) | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
AU2005240078A1 (en) * | 2004-04-30 | 2005-11-17 | Allergan, Inc. | Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing |
US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
US7998717B2 (en) * | 2005-12-02 | 2011-08-16 | Pacific Biosciences Of California, Inc. | Mitigation of photodamage in analytical reactions |
US20070260203A1 (en) * | 2006-05-04 | 2007-11-08 | Allergan, Inc. | Vasoactive agent intraocular implant |
US8969415B2 (en) * | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
US8492334B2 (en) | 2007-06-21 | 2013-07-23 | Yale University | Sustained intraocular delivery of drugs from biodegradable polymeric microparticles |
US10064819B2 (en) | 2008-05-12 | 2018-09-04 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
CN102026599A (zh) | 2008-05-12 | 2011-04-20 | 犹他大学研究基金会 | 眼内药物递送装置及相关方法 |
US9095404B2 (en) | 2008-05-12 | 2015-08-04 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
US9877973B2 (en) | 2008-05-12 | 2018-01-30 | University Of Utah Research Foundation | Intraocular drug delivery device and associated methods |
US20110206773A1 (en) * | 2008-05-20 | 2011-08-25 | Yale University | Sustained delivery of drugs from biodegradable polymeric microparticles |
WO2009143288A1 (en) * | 2008-05-20 | 2009-11-26 | Yale University | Biodegradable sustained-release polymeric microparticulates comprising a hydrophobic drug and determined for ophthalmic use |
JP5890182B2 (ja) * | 2009-02-12 | 2016-03-22 | インセプト エルエルシー | ヒドロゲルプラグによる薬物送達 |
US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
US8529492B2 (en) | 2009-12-23 | 2013-09-10 | Trascend Medical, Inc. | Drug delivery devices and methods |
US8834847B2 (en) | 2010-08-12 | 2014-09-16 | Pacific Biosciences Of California, Inc. | Photodamage mitigation compounds and systems |
EP2613776B1 (en) * | 2010-09-01 | 2020-07-29 | Thomas Jefferson University | Composition and method for muscle repair and regeneration |
US8349005B2 (en) | 2011-01-03 | 2013-01-08 | Masatoshi Murata | Method for burying implant to choroid |
RU2013157087A (ru) * | 2011-06-03 | 2015-07-20 | Аллерган, Инк. | Целевая доставка ретиноидных соединений к сальным железам |
US10245178B1 (en) | 2011-06-07 | 2019-04-02 | Glaukos Corporation | Anterior chamber drug-eluting ocular implant |
WO2013082149A1 (en) * | 2011-11-28 | 2013-06-06 | Case Western Reserve University | Polysaccharide therapeutic conjugates |
EP2918290B1 (en) * | 2012-11-08 | 2020-09-02 | Yamaguchi University | Therapeutic agent for keratoconjunctive disorders |
EP2925314B1 (en) | 2012-11-28 | 2020-04-01 | Aphios Corporation | Combination therapeutics and methods for the treatment of neurodegenerative and other diseases |
US10123988B2 (en) | 2013-03-15 | 2018-11-13 | Allergan, Inc. | Compositions including encapsulated isotretinoin and methods for use thereof |
EP3446690A1 (en) | 2013-05-22 | 2019-02-27 | Yamaguchi University | Inhibitor for retinochoroidal disorders |
EP3099290A1 (en) | 2014-01-28 | 2016-12-07 | Allergan, Inc. | Topical retinoid formulations and methods of use |
JP6655610B2 (ja) | 2014-05-29 | 2020-02-26 | グローコス コーポレーション | 制御された薬物送達機能を備えるインプラント及びそれを使用する方法 |
WO2015184453A1 (en) | 2014-05-30 | 2015-12-03 | Case Western Reserve University | Retinylamine derivitives for treatment of ocular disorders |
WO2015187840A2 (en) * | 2014-06-03 | 2015-12-10 | Duke University | Methods and formulations for treatment of ocular disorders |
US11129845B2 (en) | 2014-06-18 | 2021-09-28 | Case Western Reserve University | Compositions and methods for the delivery of nucleic acids |
US10925980B2 (en) | 2014-08-04 | 2021-02-23 | Case Western Reserve University | Molecular probes and methods of use |
US11407786B2 (en) | 2015-06-18 | 2022-08-09 | Case Western Reserve University | Compositions and methods for the delivery of nucleic acids |
WO2017040853A1 (en) | 2015-09-02 | 2017-03-09 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
US11564833B2 (en) | 2015-09-25 | 2023-01-31 | Glaukos Corporation | Punctal implants with controlled drug delivery features and methods of using same |
JP7003110B2 (ja) | 2016-04-20 | 2022-01-20 | ドーズ メディカル コーポレーション | 生体吸収性眼球薬物送達デバイス |
EP4249490A3 (en) | 2016-06-08 | 2023-12-13 | Clementia Pharmaceuticals Inc. | Methods for treating heterotopic ossification |
KR20190100187A (ko) | 2016-11-16 | 2019-08-28 | 클레멘티아 파마슈티컬즈, 인크. | 다중 골연골종(mo)을 치료하는 방법 |
CN111358766A (zh) * | 2020-04-13 | 2020-07-03 | 青岛大学 | 一种包载他扎罗汀的plga纳米粒及其制备方法、用途 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5824685A (en) * | 1995-02-01 | 1998-10-20 | The Johns Hopkins University School Of Medicine | Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists |
US5773019A (en) * | 1995-09-27 | 1998-06-30 | The University Of Kentucky Research Foundation | Implantable controlled release device to deliver drugs directly to an internal portion of the body |
US6306426B1 (en) * | 1997-08-11 | 2001-10-23 | Allergan Sales, Inc. | Implant device with a retinoid for improved biocompatibility |
WO1999007418A2 (en) * | 1997-08-11 | 1999-02-18 | Allergan Sales, Inc. | Sterile bioerodible implant device with improved biocompatability and method |
US6331313B1 (en) * | 1999-10-22 | 2001-12-18 | Oculex Pharmaceticals, Inc. | Controlled-release biocompatible ocular drug delivery implant devices and methods |
JP2002003406A (ja) * | 2000-06-21 | 2002-01-09 | Sankyo Co Ltd | 脳血管攣縮予防製剤 |
CA2432904C (en) * | 2000-12-21 | 2007-09-11 | Nektar Therapeutics | Induced phase transition method for the production of microparticles containing hydrophobic active agents |
EP1536819A4 (en) * | 2002-03-29 | 2007-10-17 | Maxim Pharm Inc | USING THE PRODUCTION OF REACTIVE OXYGEN METABOLITES (ROM) AND RELEASE INHIBITORS TO TREAT AND PREVENT INTRAOCULAR DAMAGE |
US20050009910A1 (en) * | 2003-07-10 | 2005-01-13 | Allergan, Inc. | Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug |
AU2005240078A1 (en) * | 2004-04-30 | 2005-11-17 | Allergan, Inc. | Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing |
-
2005
- 2005-04-27 AU AU2005240078A patent/AU2005240078A1/en not_active Abandoned
- 2005-04-29 WO PCT/US2005/015018 patent/WO2005107707A1/en not_active Application Discontinuation
- 2005-04-29 JP JP2007511054A patent/JP2007535563A/ja active Pending
- 2005-04-29 EP EP05757761A patent/EP1765284A1/en not_active Withdrawn
- 2005-04-29 US US11/119,024 patent/US20050271705A1/en not_active Abandoned
- 2005-04-29 BR BRPI0509459-3A patent/BRPI0509459A/pt not_active IP Right Cessation
- 2005-04-29 CA CA002565285A patent/CA2565285A1/en not_active Abandoned
- 2005-04-29 TW TW094114063A patent/TW200538163A/zh unknown
- 2005-05-02 AR ARP050101751A patent/AR056254A1/es not_active Application Discontinuation
-
2009
- 2009-02-18 US US12/388,400 patent/US20090163550A1/en not_active Abandoned
-
2010
- 2010-12-07 US US12/962,427 patent/US20110076318A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
BRPI0509459A (pt) | 2007-09-04 |
US20050271705A1 (en) | 2005-12-08 |
EP1765284A1 (en) | 2007-03-28 |
CA2565285A1 (en) | 2005-11-17 |
TW200538163A (en) | 2005-12-01 |
US20090163550A1 (en) | 2009-06-25 |
JP2007535563A (ja) | 2007-12-06 |
US20110076318A1 (en) | 2011-03-31 |
AU2005240078A1 (en) | 2005-11-17 |
WO2005107707A1 (en) | 2005-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR056254A1 (es) | SISTEMAS DE ADMINISTRACION INTRAOCULAR DE UNA DROGA DE LIBERACION SOSTENIDA QUE CONTIENE RETINOIDES, UN POLíMERO BIODEGRADABLE Y LOS METODOS RELACIONADOS | |
CO6351718A2 (es) | Suministro de liberacion sostenida de agentes activos para tratar glaucoma e hipertension ocular | |
CO6400201A2 (es) | Suministro liberado sostenido de uno o más agentes | |
AR062046A1 (es) | Soluciones oftalmicas | |
TW200605918A (en) | Biodegradable intravitreal tyrosine kinase implants | |
BRPI0510471A (pt) | derivado de estradiol ou um derivado de estratopona contendo implante intra-ocular de liberação constante bem como métodos relacionados de fabricação | |
CO2017007003A2 (es) | Formulaciones de sunitinib y métodos para uso de las mismas en el tratamiento de trastornos oculares | |
WO2014165308A3 (en) | Microsphere drug delivery system for sustained intraocular release | |
AR064078A1 (es) | Sistema de administracion de farmacos intraocular inyectable biocompatible, su uso para preparar un medicamento y proceso para su preparacion | |
AR049979A1 (es) | Composicion oftalmica util para la colocacion intraocular en un ojo de un ser humano o animal y uso de un componente corticosteroide, un componente polimerico biocompatible y un componente solvente oftalmicamente compatible en una cantidad efectiva para solubilizar el componente polimerico para prep | |
AR063619A1 (es) | Dispositivos y metodos para la administraicion de un farmaco oftalmico | |
CA3010374A1 (en) | Intraocular pressure reduction with intracameral bimatoprost implants | |
CL2016001041A1 (es) | Implante intraocular biodegradable que contiene una matriz de polimero biodegradable, polietilenglicol 3350 y una prostamida; uso del mismo en la reducción de la presion ocular en el ojo de un mamifero; aparato para administrar el implante intraocular biodegradable; y método para confeccionar un implante intraocular biodegradable. | |
WO2005107706A3 (en) | Biodegradable intravitreal tyrosine kinase inhibitors implants | |
AR039130A2 (es) | Metodo de administracion de un agente farmaceuticamente activo a un ojo humano | |
Robert et al. | A review of corneal melting after Boston Keratoprosthesis | |
BR112015019546A2 (pt) | implante de distribuição de drogas prolongado | |
EA201300272A1 (ru) | Применение фотоусиливающих агентов в ассоциации с рибофлавином, а также соответствующих офтальмологических композиций для перекрестного сшивания роговицы при лечении кератоконуса или других эктазийных расстройств роговицы | |
AR085781A1 (es) | Dispositivo y metodo para el suministro corneal de riboflavina mediante iontoforesis para el tratamiento de queratocono | |
JP2011525388A5 (US20050271705A1-20051208-C00012.png) | ||
BRPI0509339A (pt) | implantes intraoculares de liberação sustentada compreendendo um antagonista do receptor beta adrenérgico e métodos para tratar neuropatias oculares | |
AR043356A1 (es) | Dispositvo de liberacion sostenida para la administracion ocular de inhibidores de la anhidrasa carbonica y uso de inhibidores de la anhidrasa carbonica para su preparacion | |
BR112021019774A2 (pt) | Insertos oculares poliméricos dissolvíveis e método para usar os mesmos | |
BR112013018739A2 (pt) | sistema de distribuição de medicamento ocular | |
MX2022002306A (es) | Metodos de tratamiento de enfermedades oculares con un implante para la administracion sostenida de farmacos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |